A new crescent-shaped spindle for drug dissolution testing—but why a new spindle?

Dissolution Technologies

Volumn 11, Issue 4, 2004, Pages 13-18

  Qureshi, Saeed A ^a  

^a Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DILTIAZEM; PREDNISONE;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ANALYTICAL PARAMETERS; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DEVICE COMPARISON; DISSOLUTION; DISSOLUTION APPARATUS; DRUG BIOAVAILABILITY; DRUG DISSOLUTION TESTING; DRUG DOSAGE FORM; DRUG RELEASE; DRUG SOLUBILITY; EQUIPMENT DESIGN; FOOD AND DRUG ADMINISTRATION; HYDRODYNAMICS; IN VITRO IN VIVO CORRELATION; PRACTICE GUIDELINE; REPRODUCIBILITY; ROBUSTNESS; TURBULENT FLOW;

EID: 55749101070     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT110404P13     Document Type: Article

References (29)

1. USP. " General Chapter <711> Dissolution," USP 27-The United States Pharmacopeial Convention, Inc. Rockville, MD., pp. 2303-4 (2004).
2. PHRMA. Dissolution Calibration: Recommendations for Reduced Chemical Testing and Enhanced Mechanical Calibration. Pharmacopeial Forum, 26, 1149-66 (2000).
3. USP. General Chapters <1092> The Dissolution Procedure: Development and Validation. Pharmacopeial Forum. 30, 351-363 (2004).
4. Mirza, T., Grady, L. T. and Foster, T. S. Merits of Dissolution System Suitability Testing: Response to PhRMA's Proposal on Mechanical Calibration, Pharmacopeial Forum, 25(4), 1167-9 (2000).
5. Gray, V. A., Hubert, B. B. and Krasowski, J. A. Calibration of Dissolution Apparatuses 1 and 2-What to Do When Your Equipment Fails. Pharmacopeial Forum, 20, 8571-2 (1994).
6. Dissolution Testing of Immediate Release Solid Oral Dosage Forms, http: //www. fda. gov/cder/ guidance/1713bp1. pdf
7. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations, http: //www. fda. gov/cder/ guidance/1306fnl. pdf
8. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Forms Containing Certain Active Moieties/Active Ingredients Based on Biopharmaceutics Classification System, http: //www. fda. gov/cder/guidance/ 3618fnl. pdf
9. SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation, http: //www. fda. gov/cder/ guidance/cmc5. pdf
10. SUPAC-MR: Modified-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation, http: //www. fda. gov/cder/guidance/1214fnl. pdf
11. Cox, D. C., Wells, C. E., Furman W. B., Savage, T. S. and King, A. C., Systematic Error Associated with Apparatus 2 of the USP Dissolution Test II: Effects of Deviations in Vessel Curvature From That of a Sphere, J. Pharm. Sciences. 71: 395-399, (1982).
12. McCormick, T. J., Industry Perspective on Dissolution Apparatus Calibration. Dissolution Technology. 2: 12-15 (1995).
13. Moore, T. W. and Cox, D. C. An Open Response to the USP Subcommittee on Dissolution and Bioavailability (DBA). Pharmcopeial Forum. 23, 4581-2 (1997).
14. Kukura, J., Baxter, J. L., Muzzio F. J. Shear Distribution and Variability in the USP Apparatus 2 under Turbulent Conditions. Int. J. Pharm. 26: 9-17 (2004).
15. McCarthy, L. G., Kosiol, C., Healy, A. M., Bradley, G., Sexton, J. C., Corrigan, O. I. Simulating the Hydrodynamic Conditions in the United States Pharmacopeia Paddle Dissolution Apparatus. AAPS PharmSciTech; 4, 172-187 (2003).
16. Qureshi, S. A. and McGilveray, I. J. A Critical Assessment of the USP Dissolution Apparatus Suitability Test Criteria. Drug Develop. Ind. Pharm. 21, 905-92 (1995).
17. Qureshi, S. A. and McGilveray, I. J. Assessment of Pharmaceutical Quality of Furosemide Tablets From Multinational Markets. Drug Develop. Ind. Pharm., 24, 995-1005 (1998).
18. Qureshi, S. A. and McGilveray, S. A. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. Eur. J. Pharm. Sci., 7: 249-258 (1999).
19. Meyer M. C., Straughn A. B., Mhatre R. M., Shah V. P., Williams R. L., and Lesko L. J. Lack of in vivo/in vitro correlations for 50 mg and 250 mg primidone tablets. Pharm Res. 15, 1085-9 (1998).
20. Repta, A. J, Dissolution specifications for drug products. AAPS Pharmsci. (Suppl.), 2531 (1999).
21. Achanta, A. S., Gray, V. A., Cecil, T. L. and Grady, L. T. Evaluation of the Performance of Prednisone and Salicylic Acid Calibrators. Drug Develop. Ind. Pharm. 21, 1171-1182 (1995).
22. Beckett, A. N., Quach. T. T., Kurs, G. S. Improved hydrodynamics for USP apparatus 2. Dissolution Technol. 3. 1-10 (1996).
23. Cox, D. C., Wells, C. E., Furman W. B., Savage, T. S. and King, A. C. Systematic Error Associated with Apparatus 2 of the USP Dissolution Test II: Effects of Deviations in Vessel Curvature From That of a Sphere, J. Pharm. Sciences. 71, 395-399 (1982).
24. Qureshi, S. A. and Shabnam, J., Cause of high variability in drug dissolution testing and its impact on setting tolerance. Eur. J. Pharm. Sci., 12, 271-276 (2001).
25. Eddington, N. D., Ashraf, M., Augsburger, L. L., Leslie, J. L., Fossler, M. J., Lesko, L. J., Shah, V. P., Rekhi, G. S. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets. Pharm Dev Technol. 3, 535-47 (1998).
26. Qureshi, S. A. and Shabnam, J. Application of a new device (spindle) for improved characterization of drug release (dissolution) of pharmaceutical products. Eur. J. Pharm. Sci., 19: 291-7 (2003).
27. Moore, T. W. and Cox, D. C. Dissolution testing: collaborative study of the in-house NCDA #2 dissolution calibrator tablets with USP apparatus 2. Pharmacopeial Forum. 23, 4250-5, 1997.
28. USP. "Diltiazem Hydrochloride Tablets-Monograph," USP 27-The United States Pharmacopeial Convention, Inc. Rockville, MD., p. 628, 2004.
29. Morihara, M., Aoyagi, N. Kaniwa, N., Katori, N., and Kojim, S. Hydrodynamic Flows Around Tablets in Different Pharmacopeial Dissolution Tests. Drug Develop. Ind. Pharm., 28, 655-662 (2002).